Astal Lab — 360° view

Astal Lab, a company in the Pharmaceuticals industry, reported revenue of ₹108 crore and net profit of ₹9.77 crore for the September 2026 quarter.

Astal Lab (BSE: ASTALLTD) closed at ₹58.67 on 20 Nov 2026, down 31.8% over the past year. Its market capitalisation is ₹257 crore and it trades at 8.8 times earnings.

Share price
₹58.67 (20 Nov 2026)
Market cap
₹257 Cr (20 Nov 2026)
P/E
8.79 (20 Nov 2026)
Revenue
₹108 Cr (September 2026 quarter)
Net profit
₹10 Cr (September 2026 quarter)
ROCE
9.15% (FY26)
ROE
7.96% (FY26)
Book value
₹81.6 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹92.60 / ₹49.99 (20 Nov 2026)
1-year return
-31.8% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
BSE: ASTALLTD

Incorporated in 1993, Astal Laboratories Ltd is engaged in the manufacture and sale of Pharmaceutical Intermediates and Bulk Drugs

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.